Kalos Management, Inc. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.

Quarter-by-quarter ownership
Kalos Management, Inc. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$256,000
-32.8%
23,900
+1.9%
0.34%
+31.8%
Q1 2022$381,000
+12.1%
23,450
-7.5%
0.26%
+183.7%
Q4 2021$340,000
+6.9%
25,359
+7.0%
0.09%
+2.2%
Q3 2021$318,000
-19.5%
23,700
-1.5%
0.09%
-43.8%
Q2 2021$395,000
+51.9%
24,0500.0%0.16%
+97.5%
Q1 2021$260,000
+46.9%
24,050
+1.1%
0.08%
+6.6%
Q4 2020$177,000
+98.9%
23,800
-4.0%
0.08%
+90.0%
Q3 2020$89,000
-1.1%
24,800
+30.9%
0.04%
+5.3%
Q2 2020$90,000
+143.2%
18,9500.0%0.04%
+137.5%
Q1 2020$37,000
-30.2%
18,9500.0%0.02%
-23.8%
Q3 2019$53,000
-76.2%
18,950
-30.9%
0.02%
-85.4%
Q1 2019$223,000
-11.2%
27,443
-4.4%
0.14%
+18.0%
Q4 2018$251,000
+4.1%
28,700
-8.9%
0.12%
-5.4%
Q3 2018$241,000
+54.5%
31,500
-3.1%
0.13%
+81.7%
Q2 2018$156,000
-50.0%
32,500
-50.0%
0.07%
-22.8%
Q1 2018$312,000
+90.2%
65,000
+94.0%
0.09%
+19.5%
Q4 2017$164,00033,5000.08%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q2 2018
NameSharesValueWeighting ↓
DG Capital Management, LLC 1,186,726$4,076,0002.45%
Sarissa Capital Management LP 4,861,000$16,697,0001.97%
Ghost Tree Capital, LLC 1,950,000$6,698,0001.94%
ORACLE INVESTMENT MANAGEMENT INC 2,525,857$8,676,0001.14%
Eversept Partners, LP 1,143,211$3,926,9300.87%
DAFNA Capital Management LLC 749,051$2,573,0000.84%
KNOTT DAVID M 397,361$1,365,0000.80%
Parkman Healthcare Partners LLC 800,740$2,751,0000.73%
ACUTA CAPITAL PARTNERS, LLC 660,000$2,267,0000.62%
Formidable Asset Management, LLC 578,200$1,949,0000.57%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders